



SDI Review Form 1.6

Journal Name:	<u>Advances in Research</u>
Manuscript Number:	Ms_AIR_22584
Title of the Manuscript:	Proposal and point of view on targeting α-synuclein for the treatment of Parkinson's disease
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	From the article it is not clear what are currently used therapeutic strategies of the treatment of PD. It appears that the authors want to refer to the more effective treatment by blocking the production and aggregation of alpha-synuclein in PD patients (may be). What are the experiences with this therapeutic strategy? Is it only a recommendation?	In this paper, we mainly want to provide a hypothesis and some viewpoints for therapeutic strategies of the treatment of PD. Successful therapeutic management might be obtained by targeting pathogenesis of PD at different disease stages. Comprehensive prevention strategies should be adopted, such as targeting α -synuclein accumulation, synaptic dysfunction, α -synuclein hyperphosphorylation, synaptic function disorder, neuroinflammation and oxidative stress, especially focusing on neuroprotection, effective exercise rehabilitation and cognitive training, which cloud contribute to improve movement disorders and cognitive dysfunction of PD. It is only a recommendation for PD treatment.
Minor REVISION comments	The article is a few mistakes. line 54 – a-synuclein but α -sinuclein line 139 - ... drugs (NSAID) for the treatment of PD has a certain significance [17,18]. More correct is drugs (NSAID) for the treatment of PD have a certain significance [17,18]. I recommend to check English still once more	Thanks very much for your suggestions. I have corrected the mistakes and check English in this paper.
Optional/General comments	The article is written clearly and comprehensibly. It is given complete information on the status of alpha-synuclein in the pathogenesis of PD and the authors refer to the fact, when PD treatment in the early stages would be successful.	